The development of clinical symptoms, and clinical progression among persons infected with HIV-1 is the manifestation of the effects of the pathogenic viral life cycle of HIV-1. Individual variants of HIV-1 vary widely in features that determine viral fitness and virulence. HIV-1 exploits host antiviral responses, the APOBEC3G cytidine deaminase, and the low-fidelity HIV-1 reverse transcriptase, to ensure new variants with novel phenotypic features are continually present for expansion in response to changing conditions in the host, such as immune responses, or antiretroviral therapy. This highlevel variance has led to a wide range in observed fitness and virulence, across strains of HIV-1. The HIV-1 pol replication capacity assay (pol RC) measures features of viral fitness, associates with elevated CD4+ T-cell counts, yet is not strongly associated with HIV-1 RNA levels. The biological basis for elevated CD4+ T-cell counts among those carrying a virus of low pol RC may be because of lowered virus infectivity, or restricted tissue replication.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 6.Grant RM, Liegler T, Elkin C: Protease inhibitor resistant HIV-1 has marked decreased fitness in vivo. Paper presented at the 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL; February 4–8, 2001.Google Scholar
- 11.Nijhuis M, van Maarseveen NM, Schipper P, et al.: Novel HIVdrug resistance mechanism leading to protease inhibitor (PI) resistance in response to a high genetic barrier PI in vitro. Antiviral Therapy 2004, 9:42.Google Scholar
- 14.Barbour JD, Wrin T, Grant RM, et al.: Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol 2002, 76:11104–11112. This report demonstrated that viral/pol RC did not recover despite continuing viral evolution under anti-retroviral drug pressure. This suggested that the clinical phenotype of elevated CD4+ counts among patients failing a protease inhibitor-based regimen was durable.CrossRefPubMedGoogle Scholar
- 16.Deeks SG, Martin, JN, Hoh R, et al.: Continued reverse transcriptase inhibitor therapy is sufficient to maintain short-term partial suppression of multidrug resistant viremia. Paper presented at the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 10–14, 2003.Google Scholar
- 18.Barbour JD, Hecht FM, Wrin T, et al.: Persistence of primarydrug resistance mmong recently HIV-1 infected adults AIDS. 2004, 1683–1689.Google Scholar
- 19.Daar ES, Kesle K, Lail A, et al.: HIV coreceptor tropism and replication capacity predict HIV progression. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy [abstract]. Chicago, IL; September 14–17, 2003.Google Scholar
- 20.Kaur A, Grant RM, Means RE, et al.: Diverse host responses and outcomes following simian immunodeficiency virus SIVmac239 infection in sooty mangabeys and rhesus macaques. J Virol 1998, 72:9597–9611. This report demonstrates that a primate lentivirus, SIV, may replicate well in two different primate species, yet only be virulent in one, the rhesus macaque. This result emphasizes the concept that fitness and virulence are distinct features of a virus lifecycle, dependent upon the host environment.PubMedGoogle Scholar
- 23.Stoddart CA, Liegler TJ, Mammano F, et al.: Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med 2001, 7:712–718. Stoddart et al. demonstrated that protease inhibitor resistance diminished the ability of HIV-1 to replicate in human thymic tissue, and did not deplete the thymic explant of CD4+ and CD8+ thymotcytes. This result suggested that tissue-specific blocks to replication -dependent on the viral strain -may allow tissues such as the thymus to generate or expand lymphocyte populations, repopulating the periphery CD4+ T-cell population.CrossRefPubMedGoogle Scholar
- 24.Barbour J, Sinclair ES, Wrin T, et al.: CD8+ T-cell activation levels may be predicted by pol replication capacity of drug resistant and wild-type HIV1. Antiviral Therapy 2004, 9:74.Google Scholar
- 27.Glushakova S, Baibakov B, Zimmerberg J, Margolis LB: Experimental HIV infection of human lymphoid tissue: correlation of CD4+ T cell-depletion and virus syncytiuminducing/ nonsyncytium-inducing phenotype in histocultures inoculated with laboratory strains and patient isolates of HIV type 1. AIDS Res Hum Retro 1997, 13:461–471.CrossRefGoogle Scholar